Elutia (ELUT) Q3 2024 earnings summary

Executive summary

• Achieved FDA clearance for EluPro in June 2024, with first commercial use and patient implants in September and October 2024; EluPro now represents 25% of BioEnvelope sales and is adopted across all major CIED brands and neurostimulator procedures.

• SimpliDerm product line in breast reconstruction grew 19% year-over-year, driving Women's Health segment growth.

• Expanded commercial footprint with a hybrid sales model, significant new hires, and advanced GPO discussions to increase national access by early 2025.

• Engaged in confidential business development discussions and initiated a multi-center registry study for EluPro, with peer-reviewed data published on its efficacy.

• Over 100 EluPro VAC submissions and 36 active ordering accounts within six weeks of launch.

Financial highlights

• Q3 2024 net sales were $5.9 million, down 3.3% year-over-year; SimpliDerm sales rose 19% to $3.1 million, BioEnvelope sales declined 12% to $2.3 million, and Cardiovascular sales fell 40% to $0.6 million.

• GAAP gross margin was 46% (flat year-over-year); adjusted gross margin improved to 61% from 60% a year ago.

• Operating expenses increased to $13 million from $10.2 million, mainly due to higher non-cash stock-based compensation and litigation costs.

• Net income was $1.3 million, reversing a prior net loss, driven by a $12.7 million non-cash gain from warrant revaluation; adjusted EBITDA loss was $2.9 million, up from $1.7 million.

• Cash balance at September 30, 2024, was $25.7 million, bolstered by $13.8 million from warrant exercises.

Outlook and guidance

• Full commercial launch of EluPro is planned for January 2025, with expectations of favorable GPO and VA coverage decisions to expand national access.

• Management anticipates continued operating losses and negative cash flows for the foreseeable future, with substantial doubt about the ability to continue as a going concern without additional capital or asset sales.

• No formal forward-looking guidance provided.